- Home
- ABOS vs RVPH Comparison
ABOS vs RVPH Comparison
Compare ABOS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- RVPH
- Stock Information
- Founded
- ABOS 1996
- RVPH 2006
- Country
- ABOS United States
- RVPH United States
- Employees
- ABOS N/A
- RVPH N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- RVPH Health Care
- Exchange
- ABOS Nasdaq
- RVPH Nasdaq
- Market Cap
- ABOS 83.5M
- RVPH 88.0M
- IPO Year
- ABOS 2021
- RVPH N/A
- Fundamental
- Price
- ABOS $1.39
- RVPH $1.57
- Analyst Decision
- ABOS Strong Buy
- RVPH Strong Buy
- Analyst Count
- ABOS 3
- RVPH 5
- Target Price
- ABOS $9.33
- RVPH $11.40
- AVG Volume (30 Days)
- ABOS 232.9K
- RVPH 1.4M
- Earning Date
- ABOS 03-25-2025
- RVPH 04-14-2025
- Dividend Yield
- ABOS N/A
- RVPH N/A
- EPS Growth
- ABOS N/A
- RVPH N/A
- EPS
- ABOS N/A
- RVPH N/A
- Revenue
- ABOS N/A
- RVPH N/A
- Revenue This Year
- ABOS N/A
- RVPH N/A
- Revenue Next Year
- ABOS N/A
- RVPH N/A
- P/E Ratio
- ABOS N/A
- RVPH N/A
- Revenue Growth
- ABOS N/A
- RVPH N/A
- 52 Week Low
- ABOS $1.28
- RVPH $0.60
- 52 Week High
- ABOS $5.09
- RVPH $4.45
- Technical
- Relative Strength Index (RSI)
- ABOS 37.15
- RVPH 35.98
- Support Level
- ABOS $1.36
- RVPH $1.66
- Resistance Level
- ABOS $1.52
- RVPH $1.88
- Average True Range (ATR)
- ABOS 0.08
- RVPH 0.16
- MACD
- ABOS 0.01
- RVPH -0.05
- Stochastic Oscillator
- ABOS 40.30
- RVPH 7.20
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.